Insmed (NASDAQ:INSM) Posts Earnings Results, Beats Estimates By $0.61 EPS

Insmed (NASDAQ:INSM) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.61, FiscalAI reports. Insmed had a negative net margin of 76.94% and a negative return on equity of 122.43%. The company had revenue of $425.49 million during the quarter, compared to the consensus estimate of $395.50 million. During the same period last year, the firm earned ($1.70) EPS. The firm’s revenue for the quarter was up 296.1% compared to the same quarter last year.

Here are the key takeaways from Insmed’s conference call:

• BRINSUPRI launch momentum accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, with approximately 7,000 new patient starts and more than 6,300 cumulative prescribers. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.4 billion from above $1 billion.
• Insmed increased its estimated global peak sales opportunity for BRINSUPRI to more than $7 billion, citing expanding diagnosis, strong persistence and payer access, and the potential for broader use among patients with comorbid COPD or asthma. The company said prescribing depth and refill behavior are tracking at or ahead of internal expectations.
• TPIP data strengthened the company’s confidence in its pipeline centerpiece. In a 12-month PAH open-label extension, patients maintained or improved efficacy measures, 65% reached refined low-risk status, treatment continuation was 91%, and no new safety signals emerged; Phase III programs in PAH and PH-ILD are enrolling, with PPF and IPF studies planned.
• ARIKAYCE revenue rose 8% year over year to $116.3 million, while Insmed reiterated 2026 guidance of $450 million–$470 million. The company has submitted for a U.S. label expansion into newly diagnosed MAC lung disease and expects a Japanese submission in the second half of 2026, potentially supporting launches in 2027.
• Insmed reported approximately $1.2 billion in cash and reiterated expectations for cash-flow positivity in 2027 without additional capital raises, despite planned investment in TPIP Phase III trials, BRINSUPRI advertising, and Japanese commercial infrastructure. Management also noted that European commercialization is less attractive because of budget constraints and limited willingness to pay for innovation.

Insmed Price Performance

Shares of INSM traded down $1.45 on Friday, hitting $131.10. The company’s stock had a trading volume of 4,904,073 shares, compared to its average volume of 3,072,772. The company has a market capitalization of $28.42 billion, a PE ratio of -31.90 and a beta of 0.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a 50 day moving average price of $105.14 and a 200 day moving average price of $129.23.

Insiders Place Their Bets

In related news, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at $7,065,016.14. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the transaction, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. The trade was a 3.97% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 54,590 shares of company stock valued at $5,793,738. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. Transamerica Financial Advisors LLC grew its holdings in Insmed by 72.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 146 shares in the last quarter. Brooklyn Investment Group grew its holdings in Insmed by 5.7% in the 4th quarter. Brooklyn Investment Group now owns 2,839 shares of the biopharmaceutical company’s stock valued at $501,000 after buying an additional 152 shares in the last quarter. Raiffeisen Bank International AG bought a new position in Insmed during the 4th quarter worth $32,000. Finally, Insigneo Advisory Services LLC lifted its holdings in shares of Insmed by 10.2% during the fourth quarter. Insigneo Advisory Services LLC now owns 2,641 shares of the biopharmaceutical company’s stock worth $460,000 after buying an additional 245 shares in the last quarter.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
• Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
• Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
• Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
• Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Wall Street Analyst Weigh In

INSM has been the subject of several recent research reports. Roth Capital reissued a “buy” rating on shares of Insmed in a research report on Monday, June 8th. Wells Fargo & Company upped their price target on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research report on Friday. UBS Group reissued a “buy” rating and set a $172.00 price objective on shares of Insmed in a report on Friday. Cantor Fitzgerald restated an “overweight” rating and issued a $235.00 target price on shares of Insmed in a research note on Tuesday, July 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $205.26.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.